Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > AlphaRx To Present at 47th Annual ICAAC

AlphaRx Inc. , a specialty pharmaceutical company dedicated to developing the next generation of therapeutic products using nanotechnology, today announced that its Antituberculosis product candidate, Streptomycin nanoparticles, will be the subject of a slide presentation under the title "Advances in Treatment and Pathogenesis of Mycobacterial Infections" at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held September 17-20, 2007 in Chicago. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the problem of infectious diseases.

AlphaRx To Present at 47th Annual ICAAC

MARKHAM, Ontario, Canada | Posted on September 17th, 2007

Dr. Joseph Schwarz, Chief Scientist of AlphaRx is scheduled to present "Effective Treatment of Tuberculosis in Mice with Nanoparticulated Streptomycin." The presentation will elucidate that Streptomycin in the Company's nanoparticulated delivery platform, demonstrated increased efficacy and is effectively a cure of model tuberculosis at a dosage 80% lower than that of free drug, provided 100% survival in experimental TB mice model and exhibited noticeable sustained release and targeting of the incorporated drug.

For more information on AlphaRx visit, . For more information on the ICAAC 47th annual meeting, scheduled for September 17-20, 2007, visit .


About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

For more information, please click here

168 Konrad Crescent
Suite 200, Markham
Ontario, Canada L3R 9T9
Phone: 905/479-3245
Fax: 416/352-6120

Douglas Dicconson
Director, Market & Business Development

Copyright © AlphaRx Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Sniffing out cancer with improved 'electronic nose' sensors October 2nd, 2015

Hopes of improved brain implants October 1st, 2015

New Nanomaterials Taking Research to Mexico, Possibly into Space September 29th, 2015

Cristal Therapeutics Starts Clinical Phase I Trial with Nanomedicine CriPec® Docetaxel in Patients with Solid Tumours September 29th, 2015


Scientists found a natural nanostructure to control the flow of light October 4th, 2015

Industrial Nanotech, Inc. Announces New Office in Arizona to Service the Company's New Regional and National Home Builders in Arizona and Nevada October 2nd, 2015

Production of High Temperature Ceramics with Modified Properties in Iran October 2nd, 2015

ISO Approves 2 Int'l Nanotechnology-Related Standards Proposed by Iran October 2nd, 2015


Flex-ANA workshop at NCSU: Flex-ANA: An Automated System for Nanomechanical Analysis of Soft Materials — October 28 (NCSU, Raleigh, NC, US) September 30th, 2015

Nanosurf at the SYNMarburg 2015 Summer School: Nanosurf at the SYNMarburg 2015 Summer School September 30th, 2015

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC(TM) Delivery System: Data to be presented September 27 at the European Cancer Conference 2015 in Vienna September 11th, 2015

AUREA Technology will show Quantum Dots lifetime measurement at the 14th conference on Methods and Applications of Fluorescence MAF14 September 11th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic